Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EVAX
- Price
- 1.35
- Stock movement up
- +- (%)
- Company name
- Evaxion Biotech AS
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.51M
- Ent value
- 12.12M
- Price/Sales
- 0.46
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 22.97%
- 1 year return
- -93.23%
- 3 year return
- -79.18%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EVAX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.46 |
| Price to Book | - |
| EV to Sales | 3.67 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.12M |
| EPS (TTM) | -10.41 |
| FCF per share (TTM) | -1.82 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.30M |
| Gross profit (TTM) | 3.30M |
| Operating income (TTM) | -15.10M |
| Net income (TTM) | -11.50M |
| EPS (TTM) | -10.41 |
| EPS (1y forward) | -6.30 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -456.89% |
| Profit margin (TTM) | -347.99% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.58M |
| Net receivables | 0.00 |
| Total current assets | 0.00 |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 15.19M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 0.00 |
| Total liabilities | 15.19M |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.01M |
| Capital expenditures (TTM) | 1.00K |
| Free cash flow (TTM) | -2.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -75.74% |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.34 |
| Daily high | 1.38 |
| Daily low | 1.32 |
| Daily Volume | 59K |
| All-time high | 634.00 |
| 1y analyst estimate | 54.25 |
| Beta | -0.23 |
| EPS (TTM) | -10.41 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 26 May 2025 |
Downside potential
Loading...
Downside potential data
| EVAX | S&P500 | |
| Current price drop from All-time high | -99.79% | -12.89% |
| Highest price drop | -99.79% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -77.88% | -11.07% |
| Avg time to new high | 351 days | 12 days |
| Max time to new high | 862 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.51M
Marketcap category
Small-cap
Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Employees
49
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page